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RESUMO 
 
A insulina e o sistema endocanabinóide (eCB) exercem funções muito importantes no 
organismo, tanto na periferia como no cérebro. Algumas destas funções são desempenhadas 
em comum, uma vez que as vias de sinalização intracelular destes dois sistemas se 
sobrepõem. Além disso, o recetor de canabinóides do tipo 1 (CB1R) tende a formar 
heterodímeros com recetores de tirosina cinase (RTKs). Recentemente, foi demonstrado 
através de experiências de voltage-clamp em whole-cell que a perfusão de insulina induz a 
libertação de eCBs nos corpos celulares dopaminérgicos da área tegmental ventral (VTA), 
revelando a existência de uma interação direta entre a insulina e o sistema endocanabinóide 
no sistema nervoso central (CNS). 
Assim, com o objetivo de caracterizar algumas das funções da insulina no cérebro e 
perceber como é que a sua ação depende do CB1R, foram realizadas experiências de 
electrofisiologia, para medição da transmissão sináptica, e de captação de glucose. 
Com este trabalho verificou-se que o efeito da insulina na transmissão sináptica basal é 
dependente do CB1R e das condições metabólicas do organismo (jejum ou diabetes induzida 
por streptozotocina (STZ)), em fatias de hipocampo de rato. Adicionalmente, o cálculo do 
paired-pulse ratio (PPR) demonstra que a ação da insulina também é pré-sináptica. A 
insulina diminuiu também a captação de glucose, em fatias de hipocampo e de córtex de 
rato, sendo este efeito dependente do CB1R. A deleção genética do CB1R diminuiu 
igualmente a captação de glucose. Finalmente, experiências preliminares de Western blot 
indicam que tanto o recetor de insulina (InR) como o CB1R estão localizados na zona 
pós-sináptica, no córtex de ratinhos e humanos. Assim, estes resultados sugerem uma 
interação entre o InR e o CB1R no cérebro, que poderá ser direta ou indireta. Experiências 
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adicionais serão necessárias para perceber se estes dois recetores formam um heterodímero 
ou interagem indiretamente. 
 
Palavras-chave: insulina; endocanabinóides; transmissão sináptica; captação de 
glucose. 
 
 
Abstract 
XV 
 
ABSTRACT 
 
Insulin and the endocannabinoid (eCB) system have important and common functions 
in both peripheral and brain metabolism. This is due to the overlapping of their intracellular 
signalling pathways and the tendency of the cannabinoid receptor type 1 (CB1R) to form 
heterodimers with receptor tyrosine kinases (RTKs). Recently it was demonstrated by 
whole-cell voltage-clamp experiments that bath application of insulin triggers eCB release in 
ventral tegmental area (VTA) dopaminergic cell bodies, revealing a direct interaction 
between insulin and the eCB system in the central nervous system (CNS). Thus, synaptic 
transmission and glucose uptake measurements were made in order to characterize some of 
the functions of insulin in the brain and to understand if these functions depend on the CB1R. 
Here is reported that the effect of insulin on basal synaptic transmission is dependent 
on the CB1R and also on metabolic conditions like fasting or diabetes induced by 
streptozotocin (STZ), in rat hippocampal slices. Besides, a presynaptic action of insulin is 
suggested by paired-pulse ratio (PPR) calculations. Insulin also inhibited glucose uptake in a 
CB1R-dependent fashion in both hippocampal and cortical slices of fed rats. The genetic 
deletion of the CB1R also impaired glucose uptake. Finally, preliminary Western blot 
experiments suggested that both insulin receptor (InR) and CB1R are localized in the 
postsynaptic active zone of mice and human cortices. 
Hence, this work suggests an interaction between the InR and CB1R, that might be 
direct or indirect. Further experiments will be necessary to understand if these two receptors 
form or not an heterodimers. 
 
Keywords: insulin; endocannabinoids; synaptic transmission; glucose uptake. 
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1.1. Insulin 
 
1.1.1. The insulin molecule 
It was in 1923 when Frederick Grant Banting and John Rickard Macleod were jointly 
awarded the Nobel Prize in Physiology or Medicine for the discovery of insulin 
(Nobelprize.org, 1923). Since then, many discoveries have been made and now we have a 
much better understanding of the importance of insulin and its numerous signalling 
pathways. Nevertheless, there is still a lot to uncover and to understand. 
Insulin is a small protein with two polypeptide chains, A and B, joined by two 
disulphide bonds. In the periphery, insulin is synthesized in the pancreas as an inactive 
precursor called preproinsulin, which has an amino-terminal signal sequence that addresses 
its passage into secretory vesicles. Proinsulin is produced by the proteolytic cleavage of the 
signal sequence of preproinsulin and consequent formation of three disulphide bonds. It is 
stored in secretory granules in pancreatic β-cells and converted to active insulin by specific 
proteases, when blood glucose is elevated, in order to be released into the circulatory system 
(Nelson and Cox, 2005). 
 
1.1.2. Insulin signalling 
Insulin is an anabolic hormone that regulates both metabolism and gene expression. It 
promotes the synthesis and storage of carbohydrates, lipids and proteins, while inhibiting 
their degradation and release into the circulation. Insulin increases glucose uptake in muscle 
and fat, stimulating the translocation of the glucose transporter type 4 (GLUT4) from 
intracellular sites to the cell surface. It inhibits hepatic glucose production by blocking 
gluconeogenesis and glycogenolysis, acting as the main regulator of blood glucose 
Insulin signalling depends on the endocannabinoid system in the brain 
4 
concentration. Insulin also regulates the expression or activity of enzymes that catalyse 
glycogen, lipid and protein synthesis, whilst hindering the activity or expression of those that 
catalyse degradation. Thus, insulin stimulates cell growth and differentiation and promotes 
the storage of substrates in fat, liver and muscle by stimulating lipogenesis, glycogenesis and 
protein synthesis, while it inhibits lipolysis, glycogenolysis and protein breakdown (Saltiel 
and Kahn, 2001). 
Insulin signalling is mediated by a complex and highly integrated network that controls 
several processes. Its action involves a series of signalling cascades which start with insulin 
binding to its specific cell-surface receptor (Cheatham and Kahn, 1995; Cuatrecasas, 1972 
and Freychet et al., 1971), the consequent receptor autophosphorylation and activation of the 
receptor tyrosine kinases (RTKs), resulting in the phosphorylation of tyrosine residues of 
insulin receptor substrates (InRSs) (Kapeller et al., 1999; Sato et al., 1999 and Soumaya, 
2012). 
In its native conformation, the insulin receptor (InR) is composed by two identical 
α-chains and two β-subunits covalently linked through disulphide bonds to form an 
α2β2-hereotetramer (Cheatham and Kahn, 1995 and Nelson and Cox, 2005). It has two splice 
forms which are usually co-expressed in cells that also express the related insulin-like 
growth factor 1 receptor (IGF-1R), which is activated by the insulin-like growth factor 1 
(IGF-1) and can also be activated by insulin (Taniguchi et al., 2006). The InR and the 
IGF-1R belong to the class II of the subfamily of RTKs, because they both contain 
cysteine-rich motifs in their extracellular α-subunit and are disulphide-linked 
heterotetramers. The InR α-subunit contains the extracellular insulin binding domain, 
whereas the β-subunit holds sites for N- and O-linked glycosylation, a transmembrane 
domain and an intracellular domain that contains an insulin-stimulated protein tyrosine 
kinase (Cheatham and Kahn, 1995). Insulin binding to the α-subunit leads to activation of 
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the kinase activity in β-subunits, followed by transphosphorylation of those β-subunits and a 
conformational change which further increases the kinase activity (Patti and Kahn, 1998 and 
Saltiel and Kahn, 2001). Therefore, in the presence of insulin, the InR phosphorylates InRSs 
which are linked to the activation of two main signalling pathways: the phosphatidylinositol 
3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway, which starts with the activation of 
PI3K and is responsible for most of the metabolic actions of insulin, including glucose 
transport and GLUT4 translocation (Cheatham et al., 1994); and the Ras-mitogen-activated 
protein kinase (MAPK-ERK, of extracellular signal-regulated kinases) pathway, which 
regulates the expression of some genes and cooperates with the PI3K-Akt pathway to control 
cell growth and differentiation (Avruch, 1998 and Taniguchi et al., 2006). Following the 
PI3K-Akt pathway, activated (phosphorylated) Akt phosphorylates AS160 (its 160 kDa 
substrate) which, in turn, stimulates the translocation of GLUT4 from intracellular vesicles 
to the plasma membrane (Sano et al., 2003 and 2007). GLUT4 is the transporter found in 
adipose tissues and skeletal and cardiac muscle responsible for glucose uptake into the cells. 
The InR is dephosphorylated and inactivated by protein tyrosine phosphatases 
(Bourdeau et al., 2005 and Harley and Levens, 2003) like the phosphatase and tensin 
homologue (PTEN) deleted on chromosome 10, which serves as an important negative 
modulator for the PI3K-Akt pathway (Sasaoka et al., 2006; Vereshchagina et al., 2008 and 
Vinciguerra and Foti, 2006). Thus, the physiological regulation of insulin action is mainly 
controlled by the balance between phosphorylation and dephosphorylation reactions 
(Soumaya, 2012). 
 
1.1.3. Insulin resistance and diabetes 
Western lifestyle combines the easily accessible high caloric carbohydrate and fat-rich 
food, with a sedentary lifestyle leading to obesity and associated diseases. The World Health 
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Organization (WHO) has already considered overweight and obesity the fifth leading risk 
factor for global deaths and calculated that 44 % of diabetes, 23 % of ischemic heart disease 
and between 7 and 41 % of certain cancer burdens are attributable to overweight and obesity 
(Who.int, 2013). With time, the human metabolism exposed to these conditions develops 
resistance to insulin, resulting in diabetes and neuropathy in the periphery and 
neurodegenerative diseases in the brain. 
Diabetes mellitus (DM) is the most common endocrine disorder, currently affecting 
over 380 million people world-wide and prospectively over 365 million in the year 2030 
(Wild et al., 2004). DM is represented mostly by two types: type 1 or insulin-dependent DM 
(T1DM), which is mostly due to autoimmune-mediated destruction of the pancreatic islets of 
Langerhans, resulting in insulin deficiency; and type 2 diabetes or non-insulin dependent 
DM (T2DM), that is characterized by insulin resistance and is usually associated with 
abnormal insulin secretion. Most cases of diabetes are of T2DM (Bhattacharya et al., 2007; 
Zimmet, 1999 and Zimmet et al., 2001). Gestational diabetes affects 10 % of pregnant 
women and is probably a natural process, but also requires management. 
T2DM is a complex disease characterized by a combination of impaired insulin action, 
increased hepatic glucose production and insulin secretory defects. For insulin resistant 
individuals who are not diabetic, control of blood glucose levels can be arranged by 
compensatory increases in insulin secretion by pancreatic β-cells (Rhodes, 2005). But when 
insulin resistance goes along with the dysfunction of pancreatic islet β-cells this control fails. 
Therefore, together with β-cell failure, the major pathophysiological source of T2DM is the 
resistance of target tissues to insulin (Ginsberg, 2000 and Larsen, 2009). Insulin resistance is 
the initial measurable symptom in patients who are in risk of developing T2DM 
(Utzschneider et al., 2011) and also contributes to the morbidity of obesity. 
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1.1.4. Insulin in the brain 
1.1.4.1. Insulin and insulin receptors in the brain 
The brain was thought to be insulin insensitive for many years, but it has been 
suggested that insulin in the brain regulates both peripheral and central glucose metabolism, 
neurotransmission, learning and memory and confers neuroprotection (Duarte et al., 2012b). 
The presence of InRs in the central nervous system (CNS) was first demonstrated by in vitro 
binding studies (Havrankova et al., 1978a, 1981, 1983 and Plum et al., 2005). InRs were 
then identified in both neurons and glial cells of the rat brain (Wozniak et al., 1993), but 
their sub-cellular localization was found just a few years later. Using immunohistochemistry 
and western blotting techniques, the InR was localized at synapses from cultured 
hippocampal neurons (Abbott et al., 1999) as well as insulin (Baskin et al., 1983a, 1983b, 
1987; Havrankova et al., 1978a, 1981 and Plum et al., 2005). Besides, InR expression was 
also described in the olfactory bulb, hypothalamus, cerebral cortex, hippocampus and the 
pituitary intermediate lobe (Havrankova et al., 1981; Plum et al., 2005; Unger and Betz, 
1998 and van der Heide et al., 2006). 
The origin of brain insulin is still not fully understood, but it is known to be present in 
the cerebrospinal fluid (Baura et al., 1993 and Fernandez and Torrez-Alemán, 2012). 
Glucose was also shown to significantly enhance the immunoreactive insulin released in rat 
brain synaptosomes (Santos et al., 1999). Hence, it has been suggested that insulin in the 
brain can have two different sources: it can be transferred through the blood-brain barrier 
(Banks, 2004; Schwartz et al., 1992 and Woods et al. 2003), with lower concentration when 
compared to insulin levels in the blood stream; and it can also be locally synthesised (Woods 
et al., 2003 and van der Heide et al., 2006), which seems to occur in pyramidal neurons from 
hippocampus, prefrontal cortex, enthorhinal cortex and olfactory bulb, but not in glial cells 
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(Hoyer, 2003). Thus, insulin can be found in brain cortex, olfactory bulb, hippocampus, 
hypothalamus and amygdala (Havrankova et al., 1978b and Duarte et al., 2012b). 
 
1.1.4.2. Insulin signalling in the brain 
Some data also suggests that insulin is neuroprotective, having an important role in 
neuronal maintenance and survival. For instance, it was shown that insulin is capable of 
inhibiting apoptosis of cerebellar granule cells, acting through the InR rather than the 
IGF-1R (Schubert et al., 2004 and van der Heide et al., 2006). 
Just like in the periphery, insulin in the brain binds to its receptor and activates two 
signal transduction cascades: the PI3K-Akt pathway and the MAPK-ERK pathway (van der 
Heide et al., 2006). In the brain, the PI3K-Akt pathway is of a major importance because, 
among other reasons, it mediates the effects of PI3K in neuronal survival, since the 
overactivation of PI3K and Akt kinase prevents apoptosis (Philpott et al., 1997; Rodgers and 
Theibert, 2002 and van der Heide et al., 2006). On the contrary, the hypoactivity of the 
PI3K-Akt pathway leads to tau hyperphosphorylation, resulting in the retraction of neuronal 
processes and the accumulation of neurofibrillary tangles (NFTs) - both are major hallmarks 
of Alzheimer's disease (AD) (Liu et al., 2008). 
 
1.1.4.2.1. Insulin signalling and glucose metabolism in the brain 
The brain is dependent on a strictly regulated supply of glucose (Erecinska and Silver, 
1989). Glucose uptake in the brain occurs mainly through GLUT1 and GLUT3 isoforms 
(Emmanuel et al., 2013 and Mueckler, 1994), although there is evidence of expression of 
GLUT2, GLUT4, GLUT5 and GLUT8 in neurons (Choeiri et al., 2002 and Uemura and 
Greenlee, 2006). GLUT1 mediates resting glucose uptake independently of insulin action 
(Vannuci, 1994) while GLUT3 enables glucose uptake from the interstitium into neurons 
Introduction 
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(Emmanuel et al., 2013; Mueckler, 1994 and Simpson et al., 2007). In primary cultures of 
rat neurons and astroglia, glucose deficiency and hypoxia increase glucose uptake by 
facilitating the translocation of GLUT proteins to the plasma membrane (Bruckner et al., 
1999; Loike et al., 1992 and Sivitz et al., 1992). Also in culture, insulin and membrane 
depolarization combined stimulate the fusion of GLUT3 with the neuronal plasma 
membrane, resulting in increased glucose uptake (Uemura and Greenlee, 2001). Then, 
studies in human subjects with positron emission tomography (PET) showed that insulin 
modulates neural activity and, probably as a consequence, glucose uptake in those brain 
areas which are normally also involved in control of food intake, especially in regions 
related to appetite and reward as the hypothalamus and orbitofrontal cortex. Therefore, the 
lack of these responses can serve as measures of cerebral insulin resistance (Anthony et al., 
2006). 
 
1.1.4.2.2. Insulin signalling and neurotransmission 
The main inhibitory neurotransmitter in the CNS is γ-aminobutyric acid (GABA), 
which is released from the axon terminals to bind to synaptic and extrasynaptic GABAA 
channels and to decrease neuronal excitability. By this mechanism, GABA mediates phasic 
and tonic neural inhibition, respectively. It is worth noting that tonic conductance regulates 
basal neuronal excitability, it is controlled by hormones and it seems to modulate cognitive 
functions in the hippocampus (Caraiscos et al., 2004; Crestani et al., 2002; Martin et al., 
2010; Pavlov et al., 2009 and Prut et al., 2010). It was described that insulin inhibits 
spontaneous firing of rat hippocampal pyramidal neurons (Palovcik et al., 1984) and that 
insulin increases the number of GABAA channels (Wan et al., 1997). Then, it was found that 
insulin has an important effect in the hippocampal CA1 pyramidal neuronal excitability, 
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increasing the GABA mediated tonic inhibitory conductance and, consequently, decreasing 
the action potential firing frequency in the CA1 pyramidal neurons (Jin et al., 2011). 
 
1.1.4.2.3. Insulin signalling and synaptic plasticity - learning and memory 
As it was previously said, InRs have been found in higher density in the brain structure 
directly related to learning and memory, the hippocampus. In the last few years, pieces of 
evidence linking neuronal insulin signalling and cognitive function have been found in the 
hippocampus (Duarte et al., 2012b; Ghasemi et al., 2013 and McNay and Recknagel, 2011). 
For instance, it was demonstrated in animal studies that the hippocampal expression of 
proteins involved in the insulin signalling cascade increases in response to cognitive activity 
(Dou et al., 2005; McNay et al., 2010 and Zhao et al., 1999). Cognitive activity and 
long-term memory storage are centred in synaptic neural transmission and molecular 
changes at the postsynaptic density. And it was found both InRs and intracellular InRS 
proteins in that synaptic active zone (Abbott et al., 1999). Localized insulin synthesis in 
neurons and excitatory neurotransmitters induced changes in neuronal insulin signalling 
capacity (Hori et al., 2005), supporting the idea that insulin signalling affects neuronal 
activity and, specifically, hippocampal cognitive activity (Emmanuel et al., 2013). 
Short-term memory formation after a spatial learning task is also associated with an 
up-regulation of the InR mRNA in the rat hippocampal CA1 area. Increases in InR protein 
levels have also been found in hippocampal synaptic membrane fractions after short-term 
memory formation (van der Heide et al., 2006 and Zhao et al., 1999). Furthermore, specific 
defects in neuronal insulin signalling were already associated with a deficit in NMDA 
receptor-dependent synaptic plasticity in the hippocampus and loss of metaplasticity 
(modulation of synaptic plasticity by the previous activity of a synapse), which means that 
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defects in the hippocampal insulin signalling leads to cognitive deficits (Costello et al., 
2012). 
Long-term depression (LTD) is considered a synaptic mechanism underlying learning 
though new experiences in the mammalian brain (Bear and Abraham, 1996 and 
Manahan-Vaughan and Braunewell, 1999). Besides the LTD induced by low-frequency 
stimulation (LFS) at the hippocampal Schaffer collateral CA1 synapses, it was reported that 
insulin induces a protein phosphatase (PP)-independent form of LTD, or insulin-LTD. The 
insulin-LTD is induced and expressed postsynaptically and it is dependent on the activation 
of the PI3K-Akt pathway and a local protein synthesis at the synaptic site of dendrites. Thus, 
the insulin-LTD might be considered another important role of insulin in learning and 
memory (Huang et al., 2004). 
Apart from PET studies, magnetic resonance imaging (MRI) has already been used as 
an indirect but non-invasive technique to measure changes in neuronal activity levels, in 
vivo, in the brain of human subjects. These studies revealed that insulin, not only changes the 
hypothalamic response allowing us to perceive some differences between lean and obese 
subjects neural metabolism (Matsuda et al., 1999 and Smeets et al., 2005), but also that it 
influences the intrinsic brain activity besides homeostatic systems of the brain modulating 
the orbitofrontal cortex, anterior cingulate cortex, prefrontal cortex and hypothalamus 
(Kullmann et al., 2012). 
 
1.1.4.2.4. Insulin as a neuroprotective agent 
Insulin has also been shown to have an important neuroprotective role against 
damaging conditions like oxidative stress (D’Mello et al., 1993; Duarte et al., 2005, 2008; 
Gwag et al., 1997; Hamabe et al., 2003; Hong et al., 2001; Ryu et al., 1999 and Wu et al., 
2004) and reduction of neuronal apoptotic death (Duarte et al., 2005 and Fülöp et al., 2003). 
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The signalling pathway underlying this role is still under discussion. Nowadays it is thought 
to be caused by the reestablishment of InR/IGF-1R signalling gene transcription (Duarte et 
al., 2008), improving neuronal glucose metabolism (Duarte et al., 2006; Fülöp et al., 2003; 
Gerozissis, 2003 Hoyer, 2003; and Watson and Craft, 2003) and antioxidant defenses 
(Duarte et al., 2005), or by an antiapoptotic cascade involving IGF-1R and PI3K-Akt 
signalling activation with consequent prevention of caspases inactivation (Chin et al., 2005 
and Leinninger et al., 2004), or even by an antiapoptotic insulin effect, through neuronal 
stress-activated protein kinase inhibition (Kim and Han, 2005). Regardless, it is important to 
notice that some of those injuries may constitute the causes for brain dysfunction, associated 
with several pathologies (as DM), aging and age related diseases (like AD) and that insulin 
seems to play a key role in those mechanisms (Duarte et al., 2012b). 
 
1.1.4.3. Insulin-like peptide signalling in the brain 
Insulin-like peptides (ILPs) include insulin, IGF-1 and IGF-2 among others, and - like 
insulin - both IGF-1 and IGF-2 exert many effects in the brain (Fernandez and 
Torrez-Alemán, 2012). IGF-1 is produced by all cell types in the brain but its expression is 
the highest perinatally. Despite the decreased levels in adults, IGF-1 can be found in the 
cortex, hippocampus, cerebellum, brainstem, hypothalamus and spinal cord (Bach et al., 
1991 and Bondy and Lee, 1993). IGF-2 is highly produced during development in the 
choroid plexus, leptomeninges and in the hippothalamus (Ayer-le Lievre et al., 1991) but it 
is also present in the adult brain (Fernandez and Torrez-Alemán, 2012 and Stylianopouiou et 
al., 1988). 
Most studies tackling at the roles of ILPs in the brain are carried out under pathological 
conditions. The probable main source of IGFs in the adult brain is the microglia while their 
targets, IGF-1Rs, are overexpressed in neurons and astrocytes under brain injury (Walter et 
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al., 1997). IGF-1 and IGF-2 levels, as well as IGF binding protein expression change in a 
coordinated manner. Therefore, they are thought to work in a cooperative way of action in 
glia to preserve neural tissue and energy homeostasis (Lee et al., 1996 and Walter et al., 
1997). ILPs specific functions depend on the physiological context where they are found, 
conditioning their sources, pathways and effects (Fernandez and Torrez-Alemán, 2012). 
 
1.1.4.4. Insulin signalling and Alzheimer's disease 
With the ageing of the population of developed countries and the increase in life 
expectancy, the age-related metabolic and neurodegenerative diseases are becoming a global 
health problem (Correia et al., 2012). Most sporadic forms of AD are detected in the 
middle-aged and the elderly and it is the most common form of dementia, affecting more 
than 35 million people worldwide (Who.int, 2012). AD is a progressive neurodegenerative 
disease clinically characterized by gradual cognitive impairment and adaptive function, 
culminating in premature death (Moreira et al., 2009 and Querfurth and LaFerla, 2010). 
Neuropathologically, AD is recognized by the presence of intracellular NFTs, mostly 
composed of hyperphosphorylated tau protein and senile plaques, which are massive 
aggregates of the amyloid β (Aβ) peptide in the extracellular space (Castellani et al., 2010; 
Goedert and Spillantini, 2006 and Moreira et al., 2009). AD is also identified by severe 
neuronal atrophy, primarily in the entorhinal region, then at the temporal lobe, later 
progressing to the limbic system and finally to major areas of the neocortex (Braak and 
Braak, 1995). AD can have genetic causes, constituting the rare familial form, or more 
commonly it has sporadic origin (Correia et al., 2012). 
The major risk factors for sporadic AD seems to be aging, T2DM and apolipoprotein E 
type 4 allele (Corder et al., 1993; Hoyer, 2004; Irie et al., 2008; Kivipelto et al., 2002; 
Luchsinger et al., 2007 and Ott et al., 1999). Indeed, human subjects with T2DM have a 
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large increase in the risk of AD, independently of the risk for vascular dementia, when 
compared with non-diabetic subjects (Kroner, 2009). A study has already reported that more 
than 80 % of AD patients also suffer from T2DM or irregular blood glucose levels (Janson et 
al., 2004). Both AD and T2DM are diseases characterized by the presence of insoluble 
protein aggregates with fibrillar conformation in the brain and the pancreas, respectively. 
Human islet amyloid polypeptide aggregation is related to pancreatic β-cells loss, while Aβ 
aggregation is related with neuronal and synaptic function, as previously said (Ciccotosto et 
al., 2011; Correia et al., 2012 and Lim et al., 2008). Therefore, these associations suggest 
that AD and T2DM may share common pathomechanisms leading to brain cell and β-cells 
loss. Hence, AD has been termed a brain-type diabetes or a type 3 diabetes (Duarte et al., 
2012b and Kroner, 2009). 
Because of insulin's neuromodulatory functions, neurotrophic effects (Farrar et al., 
2005 and Schubert et al., 2003) and neuroprotection against apoptosis, oxidative stress, Aβ 
toxicity and ischemia (Duarte et al., 2005; Rensink et al., 2004; Ryu et al., 1999 and Voll 
and Auer, 1991), insulin deregulation was already suggested to have a role in a variety of 
neurodegenerative and psychiatric disorders, including not only AD, but also Parkinson's 
disease, Huntington' disease, depression and schizophrenia, all of them related to 
neuroinflammation and neurodegeneration (Ghasemi et al., 2013). 
 
 
1.2. The endocannabinoid system 
 
1.2.1. The discovery of the endocannabinoid system 
The study of the endocannabinoid (eCB) system started in the late 80's with the 
discovery of specific cannabinoid receptors for the pharmacological actions of 
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Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis (Nagy et al., 
2008 and Pertwee, 1997). Definitive evidence for the existence of specific cannabinoid 
receptors resulted from the demonstration of high-affinity and saturable, stereospecific 
binding sites for the synthetic radiolabelled cannabinoid agonist [
3
H]CP55940 in mouse 
brain plasma membranes, which correlated with the in vitro inhibition of andenylate cyclase 
and the in vivo analgesic effect of the compound (Devane et al., 1988 and Pacher et al., 
2006). Autoradiography with this radioligand allowed the precise localization of cannabinoid 
receptors in rat brain sections (Herkenham et al., 1991). A G protein-coupled receptor 
(GPCR) was also identified and molecular characterized as the brain receptor for 
cannabinoids (Matsuda et al., 1990) and it is now referred to as cannabinoid receptor type 1 
(CB1R) (Pacher et al., 2006). 
 
1.2.2. Cannabinoid receptors 
The CB1R is considered the most abundant GPCR in the mammalian brain but it is 
also present in a variety of peripheral tissues and cells. Besides, there is a related second 
cannabinoid GPCR, the cannabinoid receptor type 2 (CB2R), which is mostly associated with 
cells of the immune and hematopoietic systems (Munro et al., 1993), but it can also be found 
in the brain (Gong et al., 2006 and van Sickle et al., 2005), in non-parenchymal cells of the 
cirrhotic liver (Julien et al., 2005), in the endocrine pancreas (Juan-Picó et al., 2006) and in 
the bone (Idris et al., 2005; Ofek et al., 2006 and Pacher et al., 2006). 
Besides the CB1R and the CB2R, ionotropic transient receptor potential vanilloid type 
1 (TRPV1) channels also participate in eCB signalling (De Petrocellis and Di Marzo, 2010 
and Pertwee et al., 2010). TRPV1 is largely expressed in afferent peripheral sensory neurons, 
an area associated with pain sensation (Caterina and Julius, 2001) and is capable of binding 
lipophilic molecules, like N-arachidonoyl-ethanolamine (AEA, also known as anandamide) 
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(Di Marzo et al., 2002). If in one hand AEA is a partial agonist of the CB1R, on the other 
hand it is a full agonist at TRPV1 channels (Smart et al., 2000 and Zygmunt et al., 1999). 
TRPV1 channels have also been detected in the CNS, apparently regulating the synaptic 
activity (Roberts et al., 2004; Köles et al., 2013). 
 
1.2.3. Endocannabinoids and endocannabinoid biosynthesis 
The discovery of CB1R and CB2R clearly indicated that there should be endogenous 
ligands for these receptors. Hence, AEA and 2-arachidonoyl-glycerol (2-AG) were the first 
eCBs identified (Devane et al., 1992; Mechoulam et al., 1995 and Sugiura et al., 1995). 
Until now, several more cannabinoid receptor agonists have been proposed, including 
2-arachidonyl-glyceryl ether (2-AGE or noladin), O-arachidonoyl-ethanolamine 
(virodhamine) and N-arachidonoyl-dopamine (NADA) (Bisogno et al., 2000; Huang et al., 
2002 and Porter et al., 2002). 
AEA is synthesized and released into the extracellular space and synaptic cleft on 
demand of physiological or pathological stimuli (Di Marzo et al., 1994). Research on the 
class of N-acylethanolamines, to which AEA belongs, revealed that it is biosynthesised via a 
phospholipid dependent pathway, through the enzymatic hydrolysis of the corresponding 
N-acyl-phosphatidylethanolamine (NAPE) catalysed by a phospholipase D (PLD), selective 
and specific for NAPEs. NAPEs, in turn, are produced through the acyl group transfer from 
the sn-1 position of phospholipids to the N-position of phosphatidylethanolamine, catalysed 
by a Ca
2+
-dependent trans-acylase (De Petrocellis et al., 2004; Schmid et al., 1996 and 
2002). 
2-AG levels detected in cells and tissues are usually much higher than those of AEA 
and enough to activate both CB1R and CB2R (Stella et al., 1997 and Sugiura et al., 1995). 
Furthermore, 2-AG is present in many other signalling pathways and is an important 
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precursor and/or degradation product of phospho-, di-, and triglycirides and also of 
arachidonic acid. So, there are several biosynthetic pathways known for 2-AG formation 
(Ueda et al., 2013). Mainly, like AEA, 2-AG is synthesised via the hydrolysis of 
diacylglycerols (DAGs) by DAG lipase-α (DAGLα) and -β (DAGLβ) activity, at the sn-1 
position. DAG, together with inositol 1,4,5-trisphosphate (IP3), is the cleavage product of 
phosphatidylinositol 4,5-bisphosphate (PIP2) by the enzyme PLCβ, which, in turn, is 
activated by glutamate release (Maejima et al., 2001 and Varma et al., 2001). In the brain, 
2-AG synthesis may also be induced by postsynaptic neuronal depolarization, through 
increases in the intracellular Ca
2+
 promoted by voltage-gated Ca
2+
 channels (VGCCs) 
(Chevaleyre et al., 2006). DAGLs are the major biosynthetic enzymes for 2-AG in the brain, 
spinal cord, liver and other tissues and studies show that, although they have different 
contributions within each tissue, there seems to be some cooperation between DAGLα and 
DAGLβ. In the CNS, the DAGLα has shown to be more important, regulating the retrograde 
synaptic plasticity and adult neurogenesis (Best and Regehr, 2010; Gao et al., 2010; Min et 
al., 2010 and Reisenberg et al., 2012). 
Still very little is known about 2-AGE, virodhamine and NADA biosynthesis and, as 
2-AG and AEA are the major eCBs in the brain, they will not be discussed in detail in this 
work. 
After their biosynthesis, AEA and 2-AG are promptly released into the extracellular 
medium to selectively act upon the cannabinoid receptors and, in the case of AEA, also upon 
the TRPV1. For termination of eCBs effect on extracellular targets, cells reuptake them, as 
explained below (De Petrocellis et al., 2004). 
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1.2.4. Inactivation of endocannabinoids 
Inactivation of eCBs starts with their removal from their extracellular molecular targets 
and reuptake. Even though some authors defend that fatty acid amide hydrolase (FAAH) is 
enough to drive the facilitated diffusion of eCBs (Glaser et al., 2003), it is largely thought 
that AEA and 2-AG are taken up by cells through selective, saturable, 
temperature-dependent and sodium (Na
+
)-independent facilitated transport mechanisms, via 
the FAAH-like transporter and other transport proteins (Fowler, 2013 and Fu et al., 2011). 
Once inside the cell, the hydrolysis of AEA to arachidonic acid and ethanolamine is 
catalysed by the FAAH-1. FAAH is an enzyme with an alkaline optimal pH, which can be 
found in microsomal membranes, which structure revealed by X-ray cristallography also 
suggests that it might be able to integrate the plasma membrane (Bracey et al., 2002). 
FAAH-1 hydrolyzes other long-chain fatty acid amides too, like N-oleoyl-ethanolamine 
(OEA), which is an anorexigenic and neuroprotective mediator (Hansen, 2010 and Piscitelli 
and Di Marzo, 2012). Although FAAH-1 is capable of hydrolysing 2-AG to some extent 
(Blankman et al., 2007), 2-AG is mainly cleaved by monoacylglycerol lipase (MAGL) and 
also other hydrolases such as α,β-hydrolases 6 and 12 in the synapse (Dinh, et al., 2002; 
Savinainen et al., 2012 and Schlosburg et al., 2010). 2-AG, unlike AEA, can also be directly 
esterified into phospho-glycerides through phosphorylation and/or acylation of its free 
hydroxyl groups, before FAAH or MAGL hydrolysis (Di Marzo et al., 1998a, b and 1999). 
As it was previously said, 2-AG is also a precursor for arachidonic acid production in 
sensory neurons (Gammon et al., 1989). 
Both AEA and 2-AG may even be converted into the corresponding prostaglandin 
ethanolamides and prostaglandin glyceryl esters, by the cycloxygenase-2 (COX-2) and 
subsequent action of the various prostaglandin synthases, but those metabolites are not 
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capable of acting under cannabinoid or prostanoid receptors (Ross et al., 2002 and 
Woodward et al., 2001). Hence, as COX-2 catalyzes the formation of endoperoxides, eCBs 
can serve as percursors for potential new lipid mediators (Kozak et al., 2002 and Piscitelli 
and Di Marzo, 2012). Besides COX-2, AEA and 2-AG were shown to be good substrates for 
several other enzymes that oxidize polyunsaturated fatty acids, including the cytochrome 
p450 monoxygenases and lipoxygenases (Kozak and Marnett, 2002; Piscitelli and Di Marzo, 
2012 and Snider et al., 2010). Furthermore, 12,15-lipoxygenase (and subsequent lipoxin 
A4-hydrolase product) is an allosteric enhancer of the CB1R (Pamplona et al., 2012). 
Hence, AEA and 2-AG oxidation, by COX-2 or other enzymes, can result in their 
inactivation as eCBs, but might also produce other active molecules capable of changing the 
kind of signalling observed (De Petrocellis et al., 2004 and Piscitelli and Di Marzo, 2012). 
 
1.2.5. The endocannabinoid system in the brain 
1.2.5.1. AEA and 2-AG in the brain 
AEA biosynthesis in neurons seems to be similar to the pathway followed in other 
cells, being induced by postsynaptic depolarization and intracellular Ca
2+
 influx (Di Marzo, 
2011). It is synthesized by NAPE-hydrolyzing PLD (NAPE-PLD) which converts the NAPE 
precursor of AEA N-arachidonoyl-phosphatidylethanolamine (NArPE) into the eCB agonist 
(Cristino et al., 2008). NAPE-PLD expression was detected postsynaptically and also on 
axonal membranes, especially at CA3 mossy fiber terminals of the hippocampus (Cristino et 
al., 2008; Egertová et al., 2008 and Nyilas et al., 2008). NArPE was also detected in murine 
brain, testes and leukocytes (Cadas et al., 1997; Di Marzo et al., 1996 and Sugiura et al., 
1996b). Both NArPE and AEA were found with a similar distribution in several different 
brain areas (Bisogno et al., 1999a and De Petrocellis et al., 2004). 
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Like AEA, 2-AG de novo synthesis in neurons is induced by membrane depolarization 
(Bisogno et al., 1997 and Stella et al., 1997). In retrograde eCB signalling, postsynaptic 
neuronal depolarization increases intracellular Ca
2+
 through VGCCs and enhances 2-AG 
production. Postsynaptic metabotropic glutamate receptors (mGluRs) activation by 
glutamate can also lead to 2-AG formation, through PLCβ activation (Hashimotodani et al., 
2007). Both metabolic pathways are thought to converge in order to mobilize 2-AG (Castillo 
et al., 2012). An important finding for the understanding of synaptic plasticity was that PLCβ 
showed to act as a detector for simultaneous postsynaptic Ca
2+
 and GPCR signalling 
(Brenowitz and Regehr, 2005; Castillo et al., 2012; Hashimotodani et al., 2005 and Maejima 
et al., 2005). Besides, mGluRs activation was revealed as enough to mobilize eCBs to trigger 
both short- and long-term synaptic plasticity (Castillo et al., 2012 and Chevaleyre et al., 
2006). 
 
1.2.5.2. The endocannabinoid signalling in the brain 
AEA, 2-AGE and NADA are functionally more selective for CB1Rs, while 
virodhamine is more selective for CB2Rs and 2-AG is equally selective for both receptors 
(De Petrocellis et al., 2004). As already mentioned, both CB1R and CB2R are coupled to Gi/o 
proteins in most cases (Köfalvi, 2008). The prevalence of eCBs through the brain suggests 
they are primary modulators of the synaptic function and the main mechanism by which they 
do it is through retrograde signalling. 
First it was found that eCBs mediate two forms of short-term synaptic plasticity: 
depolarization-induced suppression of excitation (DSE), suppressing the glutamate release 
(Kreitzer and Regehr, 2001); and depolarization-induced suppression of inhibition (DSI), 
which results in the decrease of GABA release (in the presynaptic cell) by retrograde 
signalling of a strongly depolarized postsynaptic cell (Diana and Marty, 2004; 
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Ohno-Shosaku et al., 2001 and Wilson and Nicoll, 2002). DSE was first detected in the 
hippocampus (Diana and Marty, 2004; Wilson and Nicoll, 2002 and Zachariou et al., 2013) 
and DSI was first studied in the hippocampus (Llano et al., 1991) and the cerebellum (Pitler 
and Alger, 1992). For DSE and DSI, the release of eCBs is driven by a large increase in 
postsynaptic calcium (Best and Regehr, 2010). 
Endocannabinoids can induce another form of short-term synaptic plasticity: 
metabotropic-induced suppression of excitation (MSE) or inhibition (MSI). MSE and MSI 
are induced by the activation of some Gq/11-linked receptors which, in the hippocampus, are 
the group I of mGluRs, specifically mGluR1 and mGluR5 and the metabotropic muscarinic 
receptors (mAChRs), specifically M1 and M3 receptors (Straiker and Mackie, 2005 and 
Zachariou et al., 2013). 
Now it is also known that eCBs also mediate presynaptic forms of LTD at both 
excitatory and inhibitory synapses in the hippocampus (Chevaleyre and Castillo, 2003). 
Thus, when the glutamatergic axons are repetitively stimulated it might leads to 
homo-synaptic LTD on glutamatergic (excitatory) synapses or to hetero-synaptic LTD on 
GABAergic (inhibitory) synapses (Zachariou et al., 2013). 
 
1.2.5.3. Nonretrograde endocannabinoid signalling 
Endocannabinoids also can modulate synaptic function in a non-retrograde fashion: it 
has been found that repetitive activation of the dendritic tree of a neocortical GABAergic 
interneurons and pyramidal cells may trigger self-inhibition following locally produced 
2-AG activating somatodendritic CB1Rs in an autocrin manner (Bacci et al., 2004; Marinelli 
et al., 2008). This is likely achieved through the activation of GIRK channels and the 
consequent long-lasting hypopolarization. 
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1.2.5.4. Endocannabinoid signalling and astrocytes 
Another form of non-retrograde synaptic plasticity leads to the field of synaptic 
metaplasticity, when post-synaptic eCB release activates astroglial CB1Rs. Astrocytic CB1Rs 
are coupled to PLC-mediated increase in intracellular Ca
2+
 and subsequent vesicular 
glutamate release onto parallel synapses where this glutamate will modulate synaptic 
function acting on mGluRs (Navarrete and Araque, 2008 and 2010). 
Although in vivo studies are still controversial, recent studies serve evidence for eCB 
synthesis in oligondendrocytes, astrocytes and microglial cells (Gomez et al., 2010; 
Hashimotodani et al., 2011 and Hegyi et al., 2012). More relevant was the finding that 
astrocytes can influence eCBs signalling and mediate synaptic function. It has been recently 
observed through immunoelectron microscopy eCBs released postsynaptically acting under 
both presynaptic and astrocytic CB1Rs, at Schaffer collateral excitatory synapses of CA1 
pyramidal neurons of the hippocampus (Han et al., 2012). Also in some synapses of CA1 
pyramidal neurons, glutamate activated N-methyl-D-aspartate receptors (NMDARs) and 
triggered short-term facilitation of transmitters release, probably by stimulating mGluRs 
(Navarrete and Araque, 2008 and 2010). So, eCBs might induce a DSE and, at the same 
time, induce synaptic transmission through astrocytes, both dependent on CB1Rs (Castillo et 
al., 2012). 
Neuron-astrocyte communication mediated by eCBs has also been related to long-term 
plasticity. Presynaptic NMDARs and CB1Rs activation are known to be necessary for spike 
timing-dependent LTD (tLTD) between neocortical pyramidal neurons (Bender et al., 2006; 
Nevian and Sakmann, 2006 and Sjöström et al., 2003). But a recent study showed that 
astrocytic CB1Rs were necessary and enough to induce tLTD (Min and Nevian, 2012). 
CB1Rs anatomy and function in neocortex was already investigated and eCBs produced in 
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pyramidal neurons seem to activate astrocytic CB1Rs increase intracellular Ca
2+
, promote 
glutamate release and stimulate presynaptic NMDARs (Castillo et al., 2012; Domenici et al., 
2006; Hill et al., 2007 and Lafourcade et al., 2007). 
In addition, it was recently found that the CB1R activation inhibits not only neuronal 
but also astrocytic intermediary metabolism in the rat hippocampus (Duarte et al., 2012). 
Hence, further studies will be definitely necessary to understand this interaction between 
neurons and astrocytes. 
 
1.2.5.5. The plasticity of the endocannabinoid signalling  
The existence of several eCB ligands, the variety of synthetic pathways for the same 
ligand, the various forms of eCB release and the multiplicity of the signalling pathways 
activated through different eCB receptors make the cerebral eCB signalling redundant (Di 
Marzo and De Petrocellis, 2012 and Harkany et al., 2008), with significant roles in cellular 
adaptation and regulation of learning and memory, by mediating short- and long-term 
synaptic changes (Gerdeman and Lovinger, 2003 and Zachariou et al., 2013). By modulating 
brain metabolism plasticity, eCBs regulate several neural functions such as cognition, motor 
control, feeding behaviour and pain (Castillo et al., 2012). In vivo and in vitro experiments, 
these changes can be induced by the application of the CB1R agonists or blocked with CB1R 
antagonists (Ohno-Shosaku et al., 2001 and Wilson and Nicoll, 2001). Besides, the eCB 
signalling is intricately involved in several brain disorders such as AD, Parkinson’s and 
Huntington’s diseases, schizophrenia and depression among others (Blázquez et al., 2011; 
Köfalvi and Fritzsche, 2008; Micale et al., 2013; Mulder et al., 2011 and Pertwee, 2012), yet 
this involvement invites further studies in both animal models and man. 
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1.2.6. The endocannabinoid system in food intake and reward 
The eCB system is especially known as a food intake modulator (Banni and Di Marzo, 
2010 and DiPatrizio and Piomelli, 2012). In fact, THC and the eCBs AEA and 2-AG were 
early shown to stimulate appetite in the CNS in both animal models and human subjects (Di 
Marzo and Matias, 2005; Matias et al., 2008; Sacks et al., 1990 and Williams and Kirkham, 
1999), while antagonists reduce food consumption. Research using CB1R knockout (KO) 
models showed that the absence of the CB1R in brain prompts reduced food intake after food 
deprivation, leanness, resistance to diet-induced obesity and increased leptin sensitivity, a 
hormone that regulates appetite and reward senses (Cota et al., 2003; Di Marzo et al., 2001; 
Matias et al., 2008; and Ravinet-Trillou et al., 2004). 
Recently, it was demonstrated that diet-induced obesity in mice increases DAGLα 
levels, AEA and 2-AG synthesis and CB1R expression in the hippocampus, as well as DSI 
and eCB-LTD, but DAGLβ, MAGL and FAAH levels remained unchanged (Massa et al., 
2010). The other way around, food deprivation downregulates CB1R signalling in 
hypothalamic feeding circuits, changing eCB-LTD into LTD dependent on nitric oxide 
(Crosby et al., 2011). Besides, experiments with polyunsaturated fatty acid diet-deficient 
mice exhibited impaired eCB-LTD in prefrontal cortex and nucleus accumbens, both areas 
related to reward (Lafourcade et al., 2011). This can be either explained by a reduced 
coupling of the CB1R with its Gi/o protein or a decrease in the levels of eCB precursors due 
to their depletion in the diet. These mice also showed changes in mood and emotional 
behaviour, connecting the eCB signalling with affective behaviours, respectively (Castillo et 
al., 2012). 
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1.2.7. The endocannabinoid system and glucose homeostasis 
It has been long known that cannabis increases blood glucose levels in rats and dogs as 
a result of the decrease in glucose tolerance (Mahfouz et al., 1975; Matias et al., 2008 and de 
Pasquale et al., 1978). In rats injected intraperitoneally with a glucose load, a preceding 
injection of CB1R antagonists, including AEA, prolonged high plasma glucose levels 
(Bermúdez-Silva et al., 2006). In another experiment, high fat diet-induced obesity increased 
blood glucose levels, but the chronic treatment of these obese mice with the CB1R inverse 
agonist SR141716A (also known as Rimonabant or Acomplia) decreased glucose, insulin 
and leptin levels (Poirer et al., 2005), as well as improved the high/low density lipoproteins 
(HDL/LDL) cholesterol ratio. After 14 days of treatment, SR141716A still reduced feeding, 
blood glucose and insulin levels and increased insulin sensitivity (Doyon et al., 2006 and 
Matias et al., 2008). 
Therefore, the eCB system has been long known as a carbohydrate metabolism 
modulator (Matias et al., 2008). In fact, the CB1R inverse agonist SR141716A was 
introduced in the market a few years ago to fight cardiometabolic risk factors including low 
insulin sensitivity, high blood glucose, fatty acid and cholesterol levels and abdominal 
obesity. However, it was withdrawn due to rare but serious psychiatric side effects like 
anxiety, depression and even suicide (Christensen et al., 2007; Lazary et al., 2011 and 
McPartland, 2009). Now it is thought that those side effects are caused by the interference 
with the constitutive CB1R activity and that CB1R neutral antagonists might constitute safer 
anti-obesity drugs, because they leave the constitutive CB1R coupling to intracellular 
cascades unaffected, while dampening extra eCB tone at the CB1R signalling (Meye et al., 
2012). 
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The role of the eCBs in cerebral glucose homeostasis has been further studied in the 
last few years. Our group has previously demonstrated that 1) the CB1R KO mice has 
impaired hippocampal glucose homeostasis (Lemos et al., 2012), 2) the activation of the 
CB1R slows down the oxidative glucose metabolism in the citric acid cycle in rat 
hippocampal astrocytes and neurons (Duarte et al., 2012), 3) and finally in the streptozotocin 
(STZ) model of T1DM, the hippocampal expression of the CB1R was altered in the rat 
(Duarte et al., 2007). These altogether suggest the involvement of the eCB system in diabetic 
encephalopathy and glucose homeostasis. 
 
1.2.8. The endocannabinoid system and Alzheimer's disease 
As shown in the subchapter 1.2, the eCB system is a very complex network that 
interferes with both peripheral and central signalling pathways. It is considered a 
neuromodulatory system, regulating several neurotransmitter systems, including 
dopaminergic, cholinergic, serotoninergic, adrenergic, opiate, glutamatergic and GABAergic 
systems (Degroot et al., 2006; Farkas et al., 2012; Ferreira et al., 2012; Freund et al., 2003; 
Köfalvi et al., 2005 and Richter et al., 2012). 
The involvement of the eCB system in chronic neurodegenerative diseases has also 
been studied in the last decade, as in AD (Micale et al., 2007; Mulder et al., 2011 and 
Ramírez et al., 2005), Parkinson's and Huntington's disease (Blázquez et al., 2011; Di Marzo 
et al., 2000 and Pertwee, 2012). CB1R and CB2R are thought to act reducing excitotoxicity, 
hypothermia, inflammation (inhibiting microglia) and facilitation of neurogenesis (Pacher 
and Kunos, 2013). For instance, Sativex
®
 is a medicine composed by the mixture of THC 
and cannabidiol, approved for the treatment of spasticity in multiple sclerosis (Collin et al., 
2007 and Novotna et al., 2011). It acts on both CB1R and CB2R and recently demonstrated 
Introduction 
27 
significant neuroprotective effects in a mice model of tauopathy, making it a promising 
therapeutic agent in multi-systemic neurological disorders (Casarejos et al., 2013). 
 
 
1.3. Insulin and the CB1 receptor 
 
In the previous sections, it was summarized that both insulin and the eCB system can 
have common functions, which is due to their highly overlapping intracellular signalling 
pathway and the fact that the CB1R tends to form heterodimers with RTKs (Dalton and 
Howlett, 2012). 
Peripheral CB1R blockade facilitates while CB1R activators counteract InR signalling 
in pancreatic β-cells, suggesting a functional interaction between the CB1R and InR 
signalling (Kim et al., 2011). This lead to the discovery of that the CB1R and the InR 
establish physical and functional interactions, through a mechanism by which CB1R 
antagonists improve insulin action in insulin sensitive tissues, peripherally and 
independently of other metabolic effects of CB1Rs (Figure 1.1) (Kim et al., 2012). On the 
other hand, acute CB1Rs modulation affects skeletal muscle insulin sensitivity in mice, but 
not by CNS CB1Rs modulation (Song et al., 2011). 
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Figure 1.1. Schematic ilustration of the regulation of IR signalling by eCBs, in pancreatic β-cells. 
Binding of eCBs to CB1Rs activates the Gαi class of heterotrimeric proteins and increases the 
association between Gαi and the IR that counteracts the effects of insulin on autophosphorylation and 
kinase activity of the IR (adapted from Kim et al., 2012). 
 
Very recently, it was demonstrated in whole-cell voltage-clamp recording that bath 
application of insulin triggers eCB release, acting at the presynaptic glutamatergic terminals 
stimulating dopaminergic activity, in ventral tegmental area (VTA) dopaminergic cell 
bodies. This might represent a new mechanism of postprandial feedback, related to satiety 
(Labouèbe et al., 2013). But more importantly than pointing to a new type of LTD mediated 
by eCBs, these results reveal a direct interaction between insulin and the eCB system in the 
CNS. 
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1.4. Aims 
 
The main aim of this study is to characterise some of the functions of insulin in the 
brain, with emphasis in synaptic transmission and glucose uptake. 
The dependence of the action of insulin on the CB1R will also be explored, with an 
attempt to characterize the molecular substrates responsible for this possible interaction, such 
as a direct heterodimer vs. indirect action through eCBs release. 
 
  
 
  
 
 
 
 
 
2. MATERIALS AND METHODS 
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2.1. Samples 
 
2.1.1. Animals 
All experiments were performed in accordance with the principles and procedures 
outlined as “3Rs” in the European Union (EU) guidelines (directive 86/609/EEC), the 
Federation of Laboratory Animal Science Associations (FELASA) and the National Centre 
for 3Rs (Kilkenny et al., 2010), and were approved by the Animal Care Committee of the 
Center for Neuroscience and Cell Biology of Coimbra. The ARRIVE guideline for the 
design and the execution of in vitro pharmacological experiments and for data management 
and interpretation was also applied (McGrath et al., 2010). 
Male Wistar rats (180-240 g, 6-13-week old) and C57BL/6j mice (28-32 g, 8-10-week 
old) were purchased from Charles-River (Barcelona, Spain). CB1R KO mice on the CD-1 
strain (Ledent et al., 1999) and their wild-type littermates were genotyped and provided by 
collaborators (Catherine Ledent, IRIBHN, Brussels). Animals were housed in a conventional 
facility, with a 12 h light/dark cycle and ad libitum access to food and water. All efforts were 
made to reduce the number of animals used and to minimize their stress and discomfort. 
In a group of these rats, we induced insulin-dependent diabetes with a single injection 
of STZ (Calbiochem, Merck Biosciences, Germany). STZ was dissolved in citrate buffer 
(226 mM, pH 4.5) and injected intraperitonealy one high dose of 60 mg/kg body weight in 
rats fasted for 5 h (7 weeks old). 
Blood glucose was determined using an Accu-Chek® system (Roche) and body 
weights were measured 3 and 15 days after injection. Rats were considered diabetic when 
their non-fasted blood glucose levels were ≥ 300 mg/dL. Up to two of these diabetic animals 
were kept in cages for 15 days with elevated grid bottom due to frequent urination. They 
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were frequently evaluated by two independent researchers for levels of suffering, according 
to FELASA recommendations, and received ad libitum food and water and daily change of 
bedding. 
Another group of rats was food-restricted for 16 hours until sacrifice (fasted rats). 
These animals were housed individually in grid bottom cages to avoid the consumption of 
the bedding or the fur of the cage mates, but otherwise housed as above. 
Animals were deeply anesthetized with halothane (no reaction to handling or tail 
pinch, while still breathing) before decapitation with a guillotine (rats) or scissors (mice), 
between 10:00 and 14:00 o’clock to reduce putative circadian hormonal effects. Hippocampi 
and cortices were removed and sliced or homogenized, depending on the aim of the 
experiment. 
 
2.1.2. Human samples 
Human samples were obtained at autopsy from the National Institute of Legal 
Medicine of Coimbra, Portugal, thanks to the collaboration between Beatriz da Silva and the 
Purines’ group in Center for Neuroscience and Cell Biology of Coimbra (CNC), headed by 
Rodrigo A. Cunha. Samples were generously provided by Paula M. Canas. 
 
 
2.2. Experimental procedures 
 
2.2.1. Extracellular electrophysiology 
2.2.1.1. Hippocampal slices preparation for electrophysiology recordings 
Hippocampal slices were prepared from 8-13 week-old Wistar rats of the three groups 
(control, STZ and fasted) using standard techniques (Costenla et al., 2011 and Sebastião et 
Materials and methods 
35 
al., 2000). Brains were rapidly removed and placed in ice-cold modified artificial 
cerebrospinal fluid (ACSF) containing in mM: 124 NaCl, 3 KCl, 2 CaCl2, 1 MgSO4, 26 
NaHCO3, 1.25 NaH2PO4 and 10 D-glucose, pH 7.4, saturated and continuously gassed with 
with a mixture of 95 % O2 and 5 % CO2. The isolated hippocampi were transversely cut in 
400 μm-thick slices using a McIlwain tissue chopper and allowed to recover in the ACSF 
solution, previously and continuously oxygenated at room temperature, for at least 60 min. 
Hippocampal slices were then transferred to a recording chamber (Harvard Apparatus, CT, 
USA) and continuously superfused at a rate of 2 to 3 mL/min with oxygenated ACSF 
solution, at 30.5 ºC, during electrophysiology recordings. 
 
2.2.1.2. Electrophysiology recordings protocol 
A bipolar stainless steel stimulating electrode was placed on the Schäffer collateral 
fibers of the hippocampus to stimulate presynaptic fibers arising from the CA3 pyramidal 
cells. Slices were stimulated with a S44 stimulator (Grass Instruments, West Warwick, RI) 
once every 15 ms, with 100 μs of pulse duration. The recording electrodes were glass 
microelectrodes (1-2 MΩ) pulled on a multistage puller (Sutter P-97, Novato, CA) and filled 
with a 4 M NaCl solution. Field excitatory postsynaptic potentials (fEPSPs) were recorded in 
the CA1 pyramidal cells (Figure 2.1) and then amplified with an ISO-80 amplifier (World 
Precision Instruments, Hertfordshire, UK). Responses were digitalized using an ADC-42 
board (Pico Technologies, Pelham, NY, USA). Information was gathered about the slope. 
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Figure 2.1. Schematic illustration of electrode placements in the hippocampal slice (adapted from 
Bristol.ac.uk). 
 
Stable baseline measurements were obtained within 30 min after placing hippocampal 
slices in the recording chamber. Postsynaptic responses were recorded for at least 10 min 
prior to the application of paired pulse stimulation (PPS), when applied, or drugs perfusion. 
During this time, input/output (I/O) relations were generated by varying the stimulation 
intensity in steps of 2 μA from minimum to maximal fEPSPs amplitude (Figure 2.2). The 
baseline presynaptic stimulation was then delivered, with one pulse (Figure 2.3 A) or two 
pulses with 50 ms pulse interval and 100 μs duration (in order to induce paired pulse 
facilitation, PPF) (Figure 2.3 B), using a stimulation intensity that evoked approximately 
60 % of maximal postsynaptic response (stimulus amplitude range between 5 and 7.2 μA). 
The evoked responses were considered stable, forming a baseline, when changed less than 
10 % for 10 min of recording and the signal obtained had a shape similar to the one 
exemplified in Figure 2.4. Then, insulin (300 nM) and/or the CB1R neutral antagonist 
O-2050 (500 nM) (Meye et al., 2012) were bath applied alone for 15-20 min, then in 
combination. 
All results were monitored and treated using the WinLTP 2.01 software (Anderson, 
2012). 
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Figure 2.2. (A) Input/output (I/O) curve example, obtained by varying the stimulation intensity in 
steps of 2 μA from (B) minimum to (C) maximal fEPSPs amplitude. 
 
 
Figure 2.3. Experimental design for (A) extracellular recording of fEPSPs and (B) for paired pulse 
facilitation (PPF). 
 
 
Figure 2.4. Shape of a stable hippocampal fEPSPs. 
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2.2.2. Glucose uptake 
2.2.2.1. Hippocampal and cortex slices preparation for glucose uptake 
experiments 
Hippocampal and cortex slices were prepared from 7-13 week-old Wistar rats and 
CD-1 WT and CB1R KO mice using a previously optimized procedure (Lemos et al., 2012). 
Brains were rapidly removed and collected into ice-cold Krebs’-HEPES solution 
(composition in mM): 113 NaCl, 3 KCl, 2.5 CaCl2, 1.2 MgSO4, 25 NaHCO3, 1.2 KH2PO4, 
10 HEPES and 5.5 D-glucose, pH 7.4, saturated and continuously gassed with a mixture of 
95 % O2 and 5 % CO2). Transversal 450 μm-thick hippocampal and cortical slices were cut 
using a McIlwain tissue chopper (Ted Pella, CA, USA). It was previously characterized with 
50 μm steps from 300 μm to 1 mm thickness that 450 μm is optimal for oxygenation, drug 
penetration in the centre of the slice vs. physical resistance (Lemos et al., 2012). Slices were 
gently separated in the same assay solution and allowed to recover for 1 h to reach 
steady-state glucose uptake/metabolism in the slice (Lemos et al., 2012), in a multichamber 
slice incubator, in 50 ml of assay solution, under continuous carboxigenation at 37 ºC. 
 
2.2.2.2. Glucose uptake protocol 
After 60 min of recovery incubation, drugs (the CB1R agonist WIN55212-2 (500 nM), 
O-2050 (500 nM), insulin (30 and 300 nM), the GABAA receptor (GABAAR) antagonist 
bicuculline (20 µM) or the sodium channel blocker tetrodotoxin (1 µM)) were added into the 
incubating bath. Five min later, the radioactive analogue 2-
3
H(N)-deoxy-D-glucose ([
3
H]DG, 
2.5 nM, 60 Ci/mmol, ARC) was bath applied for 30 min. In the end of the incubation time, 
slices were washed twice in the iced-cold assay solution and denatured in 1 mL of 0.5 M 
NaOH. 
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After dissolving the slices in NaOH, 800 μl of the samples were assayed for 3H 
(X disintegration/minute, dpm) count with the help of a Tricarb β-counter (PerkinElmer, 
USA), and the rest for protein concentration (P·mg) with the bicinchoninic acid assay 
(Merck Biosciences, Germany). The incubation bath containing the radioactive glucose 
analogue was also sampled and assayed for 
3
H: 181.8 µl volume of the assay solution 
contains 1 µmol amount of cold glucose molecules in a 5.5 mM glucose solution, which is 
represented as A dpm 
3
H. This allows calculating how many nanomoles of glucose 
(cold + radioactive) represent the actual count in the slices, which finally can be expressed as 
nmol·(mg of protein)
-1
. Note that the same figures are obtained when the X dpm values with 
the specific isotope activities (dpm/mmol) are transformed into nmol 
3
H (Lemos et al., 
2012). 
 
 
2.2.3. Western blotting 
2.2.3.1. Preparation of samples for Western blotting 
Total synaptosomal fraction, the pre- and post-synaptic active zone and the 
extra-synaptic fractions of mice and human cortices were prepared as previously described 
(Köfalvi et al., 2005; Phillips et al., 2001 and Rebola et al., 2005). Briefly, cortices from 10 
mice C57BL/6j and a sample of a human cortex were homogenized with a Teflon potter, at 
4 ºC in 2 mL of 0.32 M sucrose solution (containing 0.1 mM CaCl2 and 1 mM MgCl2). 
Twelve milliliters of 2 M sucrose solution and 5 mL of 0.1 mM CaCl2 were added to the 
resulting homogenates and were resuspended. Solutions were distributed into centrifuge 
tubes and filled carefully onto the top with 1 M sucrose solution containing 0.1 mM CaCl2. 
Those tubes were centrifuged in a SW41Ti rotor (Beckman Coulter) at 100,000 g for 3 h at 
4 ºC. The middle layer, between the 1.25 M and 1 M sucrose interphase, corresponded to 
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synaptosomes which were collected. Synaptosomes were ten times diluted in 0.32 M sucrose 
solution and centrifuged at 15,000 g for 30 min at 4 ºC with an Avanti J-26 XPI rotor 
(Beckman Coulter). The pellets were resuspended in sucrose solution and part of it was 
centrifuged again at 12,000 g for 5 min, resuspended in SDS 5 % and collected as the total 
synaptosomal fraction. 
The protease inhibitor phenylmethylsulfonyl fluoride (PMSF, 0.1 mM final 
concentration) was added freshly to the remaining portion of the synaptosomal suspension, 
which was then slowly ten-times diluted with a 0.1 mM CaCl2 solution. The same volume of 
solubilisation buffer (2 % Triton X-100, 40 mM Tris, at pH 6.0) was added to the solutions 
and they were re-incubated for 30 min on ice with mild agitation. The insoluble material 
(synaptic junctions, which represent both pre and postsynaptic fractions) was pelleted at 
40,000 g for 30 min at 4 ºC. The supernatant represents the extrasynaptic fraction. The 
synaptic junction pellet was washed with solubilisation buffer (1 % Triton X-100 in 20 mM 
Tris, at pH 6.0) and resuspended in a second buffer (1 % Triton X-100, 20 mM Tris, at pH 
8.0). This increase in pH allowed the dissociation of the extracellular matrix that maintains 
the presynaptic active zone tightly bound to the postsynaptic density. The active zone was 
solubilised while the postsynaptic density was preserved because the amount of detergent 
was not enough for its solubilisation (Köfalvi et al., 2005; Phillips et al., 2001 and Rebola et 
al., 2005). After incubation for 30 min on ice with mild agitation, the mixture was 
centrifuged at 40,000 g for 30 min. The pellet corresponded to the postsynaptic fraction and 
was resuspended in SDS 5 %. The supernatant represented the presynaptic fraction. All the 
fractions were further concentrated by overnight treatment with 30-40 mL of pre-cooled 
acetone (-20 ºC). Solutions with the acetone were centrifuged at 18,000 g for 30 min at 
-15 ºC, with a SS34 rotor in a Sorvall centrifuge (Thermo Fisher Scientific). Pellets were left 
to dry in the incubator and finally resuspended in SDS 5 %. Protein concentration was 
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determined by the BCA assay and samples were added to an equal volume of 2-times 
concentrated SDS-PAGE sample buffer before freezing at -20 ºC. 
 
2.2.3.2. Western blotting protocol 
Western blot analysis was carried out in total synaptosomes fraction and synaptosomal 
active zone (pre, post and extrasynaptic fractions) of mice and human cortices, as previously 
described by us (Köfalvi et al., 2005; Köles et al., 2013; Rebola et al., 2002 and Rebola et 
al., 2005). Briefly, each sample was denatured at 80 ºC, for 5 min. Then, the samples 
containing 1-2 µg of protein were loaded in the wells of the concentrating gel and the 
proteins were separated by SDS-PAGE (10 % with a 4 % concentrating gel) electrophoresis 
under reducing conditions, together with pre-stained molecular weight markers (Amersham, 
GE Healthcare). Next, proteins were electrotransferred to polyvinylidene difluoride 
membranes (PVDF of 0.45 µm; GE Healthcare; previously activated with pure methanol for 
10 s, followed by rinsing in mili-Q water for 5 min and then in 10 % 
N-cyclohexyl-3-aminopropanesulfonic acid (CAPS)/methanol for more than 10 min). After 
blocking for 1 h at room temperature with 3 % bovine serum albumine (BSA) in 
Tris-buffered saline containing 0.1 % Tween 20 (TBS-T), membranes were washed and 
incubated overnight at 4 ºC with the primary antibodies against InRβ (1:500 diluted in the 
blockage solution) and CB1R (1:500 dilution). Controls were made with SNAP-25 (1:40,000 
dilution), PSD-95 (1:20,000 dilution) and synaptophysin (1:20,000 dilution) primary 
antibodies. Afterwards, membranes were washed three times, 15 min each, in TBS-T and 
incubated with alkaline phosphatase-conjugated secondary antibody (1:20,000 dilution; 
Table 1) in TBS-T containing 3 % BSA, for 2 h at room temperature. After three consecutive 
washes in TBS-T with 3 % BSA, membranes were exposed to enhanced chemi-fluorescence 
reagent (ECF) for 1 min and 20 s and subsequently scanned with a VersaDoc 3000 and 
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Quantity One software (Bio-Rad Laboratories, Amadora, Portugal). The generated 
photographs were analysed using the ImageLab (Bio-Rad) software. 
 
 
2.3. Data treatment 
 
Results are presented as mean ± SEM (standard error of the mean), with the number of 
independent experiments (n) represented in each figure and statistical significance was 
considered at p ≤ 0.05. Statistical data and graphs were produced using Microsoft Office 
Excel and GraphPad Prism 5 software. 
 
 
2.4. Chemicals 
 
NaCl, KCl, NaOH, HEPES and D-glucose were purchased from Calbiochem, Merck 
Biosciences (Germany). CaCl2, MgSO4, NaHCO3, KH2PO4, NaH2PO4.H2O and DMSO were 
purchased from Sigma-Aldrich (Sintra, Portugal). Tested drugs (WIN55212-2, O-2050, 
insulin, bicuculline and tetrodotoxin) were obtained from Tocris Bioscience (UK). 
Non-water soluble substances were dissolved or reconstituted in DMSO and stored at -20 ºC 
until use. 
Primary and secondary antibodies used in Western blot analysis are resumed in 
Table 1. 
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Table 1. Primary and secondary antibodies used in Western blot analysis. 
Antibody Supplier Host Type Dilution 
Insulin Rβ (C-19) 
Santa Cruz 
Biotechnology 
(California, USA) 
Rabbit Polyclonal 1:500 
CB1-Rb-Af380 
Frontier Institute 
(Hokkaido, Japan) 
Rabbit Polyclonal 1:500 
SNAP-25 
Sigma-Aldrich 
(Sintra, Portugal) 
Mouse Monoclonal 1:40,000 
PSD-95 
Sigma-Aldrich 
(Sintra, Portugal) 
Mouse Monoclonal 1:20,000 
Synaptophysin Millipore Rabbit Polyclonal 1:20,000 
Rabbit-alkaline 
phosphatase 
conjugate 
GE Healthcare 
Biosciences (UK) 
Goat IgG + IgM (H+L) 1:20,000 
Mouse-alkaline 
phosphatase 
conjugate 
GE Healthcare 
Biosciences (UK) 
Goat IgG (H+L) 1:20,000 
 
 
  
 
  
 
 
 
 
 
3. RESULTS AND DISCUSSION 
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3.1. The effect of insulin on basal synaptic plasticity is dependent on the CB1R 
and metabolic conditions in the rat hippocampal slices. 
 
Impaired response to acutely administered insulin in neuronal activity can be measured 
by MRI and is a marker of (developing) cerebral insulin resistance (Guthof et al., 2010; 
Kullmann et al., 2012 and Tschritter et al., 2006). Considering that insulin and CB1R 
agonists both can control and affect neuronal activity and furthermore, synaptic plasticity, 
we carried out extracellular electrophysiology recordings, with modifications to our previous 
study (Martire et al., 2011), with the aim of measuring the effect of insulin on synaptic 
transmission and its dependence on the CB1R in rat hippocampal slices. 
To define whether the modulation of synaptic transmission by insulin is dependent on 
the activation of the CB1R, we tested insulin under the presence or the absence of the neutral 
CB1R antagonist, O-2050 (Wiley et al., 2011) (Figures 3.1-3.6). Extracellular recording was 
performed in hippocampal slices of young adult male Wistar rat (Figure 3.1). Fasted rats, 
which were food-restricted for 16 hours until sacrifice (Higaki et al., 1999) and rats injected 
intraperitonealy with STZ two weeks before sacrifice were also included in these 
experiments with the aim of understanding the effect of insulin and O-2050 (i.e. endogenous 
CB1R tone) on action on synaptic transmission under different metabolic conditions. 
Insulin (300 nM) statistically significantly and transiently depressed synaptic 
transmission in the first 5 min of its perfusion, as observed with the help extracellular 
recording in acute transversal hippocampal slices from ad libitum fed rats (n = 19; Figures 
3.1 A and 3.4). In contrast, slow perfusion of the CB1R antagonist O-2050 (500 nM) 
alleviated synaptic transmission from an apparent inhibitory tone, which effect became 
statistically significant after 5 min (n = 12; Figures 3.1 B and 3.4). After letting insulin’s 
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effect stabilize for 20 min, O-2050 was added for 15 min in the presence of insulin, which 
facilitated synaptic transmission similarly to that seen in the absence of insulin (n = 12; 
Figures 3.1 C and 3.4). This indicates that insulin does not prevent eCB tone in the 
hippocampal slices of the fed rats. In the other way around, after the 20 min stabilization of 
the synaptic transmission in the presence of O-2050, insulin’s effect was largely prevented: 
although at individual time points it was significantly different from the previous 10 min of 
the drug-naïve (preinsulin) baseline (Figure 3.1 D), the overall effect of insulin in the first 
5 min or the following 10 min was no longer statistically significantly different from zero 
(n = 12; Figure 3.4). This suggests that the effect of insulin is dependent on the CB1R in fed 
animals. 
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Figure 3.1. Insulin depresses basal synaptic transmission in a CB1R-dependent fashion in 
hippocampal slices of the fed rat. (A-D) Time course of the slope variation (mV/ms) of fEPSPs in 
hippocampal slices of ad libitum fed rats, upon the perfusion of (A) insulin (300 nM), (B) O-2050 
(500 nM), (C) O-2050 after 20 min stabilization of baseline in the presence of insulin and, finally, 
(D) insulin after 20 min stabilization of the baseline in the presence of O-2050. (E-F) Representative 
traces of fEPSPs from the above experiments. Data are mean ± SEM of n ≥ 12 independent 
observations, *p < 0.05, **p < 0.01. 
 
The subsequent experiments clearly supported that the hippocampal action of insulin 
and eCBs is not mechanistic as it is subject to modulation by different metabolic states. For 
instance in fasted rats, insulin’s action was drastically different as it induced a rapid and 
sustained facilitation of synaptic transmission (n = 8; Figures 3.2 A and 3.4), which effect 
was statistically significantly different from that in the ad libitum fed animals (p < 0.0001, as 
compared with Two-Way ANOVA to the data from the fed rats). Similarly to the inversion 
of insulin effect in the fasted animal, the facilitator effect of O-2050 was statistically 
significantly smaller in the fasted rats (n = 8, p < 0.05 vs. fed rats, compared with Two-Way 
ANOVA; Figures 3.2 B and 3.4). Interestingly, in the presence of insulin, O-2050 failed to 
affect basal transmission and, thus, these data were significantly different from those 
obtained in the ad libitum fed animals (n = 8, p < 0.0001 vs. fed rats, compared with 
Two-Way ANOVA; Figures 3.2 C and 3.4). Perhaps the most surprising and striking result 
was that preincubation with O-2050 fully reverted the action of insulin to what was seen in 
the fed rats in the absence of O-2050 (compare Figures 3.1 A vs. 3.2 D), and hence the 
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inhibitory effect of insulin was statistically significantly greater in the fasted rats than in the 
fed ones in the presence after O-2050 (n = 8, p < 0.05 vs. fed rats, compared with Two-Way 
ANOVA; Figures 3.2 D and 3.4). 
 
 
 
Figure 3.2. Insulin facilitates basal synaptic transmission in a CB1R-dependent fashion in 
hippocampal slices of the fasted rat. (A-D) Time course of the slope variation (mV/ms) of fEPSPs 
in hippocampal slices of 16 h fasted rats, upon the perfusion of (A) insulin (300 nM), (B) O-2050 
(500 nM), (C) O-2050 after 20 min stabilization of baseline in the presence of insulin and, finally, 
(D) insulin after 20 min stabilization of the baseline in the presence of O-2050. (E-F) Representative 
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traces of fEPSPs from the above experiments. Data are mean ± SEM of n ≥ 12 independent 
observations, *p < 0.05, **p < 0.01. 
 
Two weeks after STZ injection, insulin and O-2050 failed to alter synaptic 
transmission alone or in combination (n = 11; Figure 3.3) in the hippocampal slices, beyond 
tendency. This points out a rapid subacute remodelling of the eCB and insulin signalling 
systems, which is also reflected in other presynaptic differences measured by us as 
paired-pulse ratio (PPR; see below). 
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Figure 3.3. Insulin and CB1R blockade fail to affect basal synaptic transmission in hippocampal 
slices of the diabetic rat. (A-D) Time course of the slope variation (mV/ms) of fEPSPs in 
hippocampal slices of diabetic rats 2 weeks post-injection, upon the perfusion of (A) insulin 
(300 nM), (B) O-2050 (500 nM), (C) O-2050 after 20 min stabilization of baseline in the presence of 
insulin and finally, (D) insulin after 20 min stabilization of the baseline in the presence of O-2050. 
(E-F) Representative traces of fEPSPs from the above experiments. Data are mean ± SEM of n ≥ 12 
independent observations, *p < 0.05. 
 
 
Figure 3.4. Bar graphs summarizing the average changes in synaptic transmission from the 
extracellular recording experiments. Average slope variation (mV/ms) of fEPSPs in hippocampal 
slices of fed, fasted and diabetic rats (A) from the first 5 minutes of treatment and (B) from the 6th to 
the 15th minutes of treatment with O-2050 (500 nM) or/and insulin (300 nM). (+) denotes if the 
substance was present before the substance marked with (++), while (-) marks the absence of either 
O-2050 or insulin. Data are mean ± SEM of n ≥ 8 independent experiments, *p < 0.05, **p < 0.01. 
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3.2. The subsynaptic side for insuline’s action. 
 
Paired-pulse ratio calculations were carried out alongside the above experiments, i.e. 
while the above experiments under point 3.1 represent exclusively changes in the response to 
the first stimulus; here we monitored the change of the response to each second stimulus 
which followed the first stimulus with a 50 ms interval. This interval is short enough to 
prevent glial and postsynaptic confounding mechanisms that could alter presynaptic release 
probability (Zucker and Regehr, 2002). In fed rats, the PPR during the drug-naïve baseline 
amounted to 1.70 ± 0.05, indicating a so-called paired-pulse facilitation (PPF) according to 
the literature (Zucker and Regehr, 2002), (n = 12; Figures 3.5 A-B and 3.6 D). The PPR 
value did not increase beyond tendency to for the fasted rats (n = 6, p > 0.05, estimated with 
One-Sample t-test against the hypothetical value of 1.70), while the diabetic rats had 
significantly increased PPR (n = 7, p < 0.05; Figures 3.5 C-F and 3.6 D). This latter finding 
indicates that in diabetes, hippocampal glutamatergic terminals are under tonic inhibition 
greater than in the ad libitum fed rats, which is in concert with the cognitive deficits and 
encephalopathy associated with type-1 diabetes (Sima, 2010). 
Insulin (300 nM) or in the presence of the CB1R antagonist O-2050 (500 nM) alone 
failed to affect the PPR in the fed rat, suggesting that insulin's effect on the synaptic 
transmission is probably not presynaptic (Figures 3.5 A and 3.6 A). However and as 
expected since the CB1R is a major presynaptic regulator of glutamatergic terminals 
(Domenici et al., 2006), O-2050 slightly but statistically significantly decreased the PPR, 
indicating the presence of a very small endogenous cannabinoid tone contributing to PPF, 
i.e. to that the PPR was greater than 1. Notably, an increase in the PPR is virtually always a 
measure of presynaptic inhibition which was uncovered by O-2050, and this well matches 
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the effect of O-2050 on the synaptic transmission. Now, what is intriguing is that insulin 
significantly increased the PPR in the presence of O-2050 which may suggest that an arising 
presynaptic action of insulin - so far hidden by endogenous CB1R activity - was now 
uncovered, contributing to the disappearance of insulin’s action on synaptic transmission 
(Figures 3.5 B and 3.6 A). 
In contrast to the small or no changes observed in fed rats, the PPR was much larger 
and significantly inhibited by either insulin or O-2050 or in combination of the two in fasted 
animals (n = 6; Figures 3.5 C-D and 3.6 B). This data suggest an increased insulin 
sensitization of neural activity by fasting in the brain which is fully the opposite in the body, 
where fasting decreases insulin sensitivity by ~55 % due to the lack of the release of the 
hepatic insulin sensitizing substance (Lautt, 2004). 
Last but not least, no PPR modulation by insulin or O-2050 or by their combination 
was observed in the diabetic rats (n = 7) bolstering our previous observation about the lack 
of eCB tone and neuromodulation by insulin in the hippocampal slices under our 
experimental settings upon diabetes. 
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Figure 3.5. The presynaptic effects of insulin and O-2050 alone or in combination as evaluated 
by changes in PPR. Time course of the effect of insulin (300 nM) and O-2050 (500 nM) alone or in 
combination as indicated by the horizontal bars, in hippocampal slices of (A-B) fed, (C-D) fasted and 
(E-F) diabetic rats. (G-H) Representative traces of fEPSPs obtained for fed, (I-J) fasted and (K-L) 
two weeks STZ rats. Data are of n ≥ 6 independent experiments. 
 
 
Figure 3.6. Mean PPRs from the above experiments. (A) Drug-naïve PPR values from fed 
(n = 12), fasted (n = 6) and diabetic (n = 7) rats. (B-D) The effect of insulin (300 nM) and O-2050 
(500 nM) alone and in combination on the PPR in hippocampal slices prepared from (A) fed, (B) 
fasted and (C) diabetic rats. All treatment-induced PPR values are expressed to the 10 min average of 
drug-naïve PPR, taken as 100 %. Combined effect PPR values were compared to the single treatment 
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PPR values with the help of paired Student’s t-test. Data are mean ± SEM of n ≥ 6 independent 
experiments, *p < 0.05, **p < 0.01, ***p < 0.001, n.s.: not significant. 
 
 
3.3. Insulin inhibits glucose uptake in a CB1R-dependent fashion. 
 
Glucose is the primary source of energy in the brain and local rates of glucose 
utilization vary with neuronal activity (Pellerin, 2008). Consequently, as insulin affects 
neuronal activity we expect that it is also measurable in the rate of glucose uptake. In fact, 
systemically or nasally applied insulin affects 
18
F-deoxyglucose PET signals in the human 
brain, which response is impaired under cerebral insulin resistance (Anthony et al., 2006; 
Baker et al., 2011 and Bingham et al., 2002). Therefore, impaired response to insulin in 
glucose utilization is an additional precious indicator of cerebral insulin resistance. 
Hence, we were interested if insulin follows the same pattern of effect on glucose 
uptake and if it is modulated by the same fashion by the CB1R blockade. Taken that, our 
protocol allows incubating several slices in the same time in different wells, unlike 
electrophysiology which allows testing one slice at once. Glucose uptake in the cortex and 
hippocampus was measured with the help of [
3
H]DG, which is virtually non-metabolizable 
and thus indicates total glucose uptake (Lemos et al., 2012). If results coincide with that of 
the electrophysiology data, this experimental setting will allow us carrying out a large-scale 
pharmacological analysis otherwise impossible due to the limitations of electrophysiology. 
Glucose uptake, as calculated from the [
3
H]DG uptake, amounted to 81.3 ± 4.1 
(n = 26) Insulin at the concentration of 300 nM but not at 30 nM (Figures 3.7 and 3.8) 
decreased glucose uptake in both fed (n = 15, p < 0.01 and p < 0.05 by One-Sample t-test) 
and fasted (n = 6, p < 0.001) animals, but not in diabetic rats (n = 6, p > 0.05), in cortical and 
Insulin signalling depends on the endocannabinoid system in the brain 
58 
hippocampal slices (respectively). Besides, fasted animals found to be significantly more 
sensitive to insulin than fed rats (Figure 3.7). 
 
 
Figure 3.7. Insulin decreases the uptake of glucose in acute cortical and hippocampal slices of 
fed (CTRL) and fasted, but not diabetic rats. Bar graph representing the uptake of glucose as 
determined from [
3
H]DG uptake in fed, fasted and diabetic rat cortical and hippocamapal slices. 
Slices of 450 µM thickness were first incubated at 37 ºC for metabolic recovery in the presence of 
5.5 mM glucose at 37 ºC under carboxygenation, then 2.5 nM [
3
H]DG was bath applied for 30 min. 
The effect of insulin (300 nM) is normalized to the respective control (100 %) and was statistically 
evaluated by One-Way ANOVA. Data are mean ± SEM of n ≥ 6 independent experiments, *p < 0.05, 
**p < 0.01 and ***p < 0.001, n.s.: not significant. 
 
Then, in order to characterize the possible involvement of the CB1R in the effect of 
insulin (30 and 300 nM) on glucose uptake, hippocampal and cortical slices of fed rats were 
incubated with insulin (30 nM and 300 nM), alone or combined with the neutral CB1R 
antagonist O-2050 (500 nM) or with the CB1R agonist, WIN55212-2 (500 nM) (Figure 3.8). 
As above detailed, insulin at the concentration of 300 nM diminished resting glucose uptake 
in both cortical and hippocampal slices while at 30 nM failed to do so (n = 12, p > 0.05; 
Figure 3.8). While O-2050 had no effect alone (n = 8, p > 0.5) it fully prevented the action of 
insulin (300 nM) in cortical and hippocampal slices. WIN55212-2 also failed to affect the 
uptake of glucose per se, in accordance with previous findings (Lemos et al., 2012), 
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however, it exerted a permissive effect for 30 nM insulin to diminish glucose uptake in the 
hippocampal slice (Figure 3.8). Thus, it appears that CB1R activation positively, while CB1R 
blockade negatively influence the action of insulin in both brain areas, and that 
electrophysiological findings, in large part, correlate with glucose uptake changes. 
Consequently, we next investigated how the effect of insulin is affected by modulating 
neuronal and synaptic activity in the slices. 
 
 
Figure 3.8. The CB1R neutral antagonist O-2050 (500 nM) prevents insulin’s action on glucose 
uptake, while the CB1R agonist WIN55212-2 (500 nM) enables it in rat acute cortical and 
hippocampal slices. Effect of the CB1R antagonist O-2050 (500 nM) or the CB1R agonist 
WIN55212-2 (500 nM) on glucose uptake, alone or in combination, in rat (A) cortical and (B) 
hippocampal slices. Data are mean ± SEM of n ≥ 8 independent experiments, *p < 0.05, **p < 0.01, 
***p < 0.001, n.s.: not significant, by One-Sample t-test against the hypothetical value of 100 %. 
 
To this end, we applied two strategies: clamping the slice at high and low activity. 
Depolarization of slices with 20 mM K
+ 
increased the uptake of glucose to 192.0 ± 22.85 % 
of CTRL in the cortex and to 157.7 ± 16.83 % of CTRL in the hippocampus of rat (for both 
cases: n = 4, p < 0.05), while 30 mM K
+ 
increased the uptake of glucose to 284.6 ± 22.73 % 
in the cortex (n = 4, p < 0.01) and to 247.7 ± 16.40 % in the hippocampus (n = 4, p < 0.05; 
Figure 3.9). These data corroborate that our experimental settings are capable to reveal 
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glucose uptake changes upon altered activity in the slice. However, under K
+
 depolarization, 
insulin was no longer able to inhibit glucose uptake (p > 0.05 vs. respective controls by 
paired-t test; Figure 3.9), indicating that its effect is occluded under clamping the circuitry at 
high activity. 
Previous studies showed that insulin potentiates postsynaptic GABAAR-dependent 
neurotransmission (Mielke and Wang, 2005 and Wan et al., 1997) and that GABAA 
potentiation can decrease the energy demand in the slice (Eintrei et al., 1999). Thus, the 
effect of insulin (300 nM) under GABAAR blockade by bicuculline (20 µM) and under the 
voltage-gated sodium channel blockade by tetrodotoxin (TTX, 1 µM) was also studied 
(Figure 3.9). Neither bicuculline nor TTX affected the uptake of glucose in the cortex and 
the hippocampus, either alone or in combination with insulin (300 nM) (for both cases: 
n = 8, p > 0.05 by One-Sample t-test; Figure 3.9). These data first tell us that the slices were 
in truly resting state as a further tentative of the inhibition of neural communication resulted 
in no more decrease in glucose uptake. Together with the data with high-K
+
 clamp, these 
results also point out that insulin’s effect is fully dependent on neuronal activity, especially, 
on GABAergic communication, in accordance with the previous reports (Mielke and Wang, 
2005 and Wan et al., 1997). 
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Figure 3.9. Clamping neuronal activity prevents insulin from affecting glucose uptake. Bar 
graph illustrates the effect of high K
+
 (20 or 30 mM), the GABAAR blocker, bicuculline (20 µM) and 
the blockade of axonal depolarization by TTX (1 µM) alone or in combination with insulin (300 nM) 
on glucose uptake in rat (A) cortical and (B) hippocampal slices. Data are mean ± SEM of n = 4-8 
independent experiments, *p < 0.05, **p < 0.01, n.s.: not significant, evaluated by One-Sample t-test 
against the hypothetical value of 100%, while between-bar comparisons were carried out with 
Student’s paired t-test. 
 
In vitro experiments on cortical and hippocampal slices of adult male CB1R KO mice 
on the CB-1 strain and their wild-type littermates were performed in order to prove the 
involvement of the CB1R in the action of insulin (30 and 300 nM) (Figure 3.10). These 
experiments were carried out on 11 pairs of wild-type and CB1R KO mice, i.e. each 
wild-type animal served as a respective control for the CB1R KO mouse in the same 
experiment. In the same protocol as above with the rat, glucose uptake amounted to 
73.4 ± 4.2 (n = 11) in the wild-type control slices. Incubation with insulin resulted in a 
significant decrease in glucose uptake in cortical and hippocampal slices of wild-type mice: 
at 30 nM by 18.49 ± 5.64 % (n = 6, p < 0.05, per One-Sample t-test) and at 300 nM by 
11.82 ± 4.74 % (n = 11, p < 0.05) in the cortex; and at 30 nM by 22.50 ± 5.78 % (n = 6, 
p < 0.05) and at 300 nM by 17.78 ± 5.33 % (n = 11, p < 0.05) in the hippocampus (Figure 
3.10). As we reported previously (Lemos et al., 2012), the genetic deletion of the CB1R 
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impaired glucose uptake (n = 11, p < 0.001, in the cortex and n = 12, p < 0.01, in the 
hippocampus). The amplitude of this impairment was virtually the same as the effect of 
insulin in the wild-type mice. Furthermore, insulin affected glucose uptake neither in cortical 
nor in hippocampal slices of the CB1R KO mice (p > 0.05, with One-Way ANOVA followed 
by Tukey's multiple comparison test; Figure 3.10). 
 
 
Figure 3.10. Insulin diminishes the uptake of glucose in acute cortical and hippocampal slices of 
the wild-type but not the CB1R KO mice. Bar graph exhibiting glucose uptake values normalized 
to the wild-type control in paired experimental setting. The action of insulin on cerebral glucose 
uptake in CB1R KO mice was compared to the respective control group (empty bars) with the help of 
One-Way ANOVA followed by Tukey's multiple comparison test, while statistical differences from 
the wild-type control value were evaluated with One-Sample t-test. Data are mean ± SEM of n ≥ 6 
independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001, n.s.: not significant. 
 
Insulin inhibited glucose uptake in rat and mice resting acute slices, similarly to what 
was previously seen in the amygdala-hippocampus of humans injected with insulin (Anthony 
et al., 2006). Intranasal insulin spray also decreased intrinsic brain activity in the 
hypothalamus and orbitofrontal cortex of healthy humans (Kullman et al., 2012). Together 
with the data presented in this chapter, these may represent the postprandial feed-back 
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mechanism that terminates food seeking behavior (Brüning et al., 2000). This was 
previously proposed when cerebral activation by intranasal insulin decreased activity in the 
brain regions required for food-seeking behaviour (Guthoff et al., 2010). A possible 
mechanism for the inhibitory effect of insulin under glucose uptake is the previously 
mentioned recruitment of postsynaptic GABAARs, which results in increased GABAergic 
inhibition of the circuitry (Mielke and Wang, 2005 and Wan et al., 1997) and, consequently, 
in decreased glucose utilization in limbic areas (Eintrei et al., 1999). GABAAR-mediated 
transmission in the resting slice is a consequence of spontaneous presynaptic release of 
GABA. The action potential blocker TTX only prevents the spontaneous release of GABA 
(Salin and Prince, 1996), which seems to be essential for the action of insulin (Figure 3.9). 
Besides, bicuculline is an antagonist of GABAARs and also inhibits the insulin's effect on 
glucose uptake (Figure 3.9). Although CB1Rs were previously found in the presynaptic 
GABAergic terminals of the rat and human hippocampus, these receptors inhibited only the 
stimulation evoked by but not the basal release of GABA (Katona et al., 1999 and 2000). 
Hence, this explains why the CB1R agonist WIN55212-2 had no effect on the uptake of 
glucose (Figure 3.8). 
Fasting increased insulin-mediated inhibition of glucose uptake in rat hippocampal and 
cortical slices (Figure 3.7). A possible justification is that has these animals have been with 
low levels of insulin for such a long time that they become more sensitive to insulin than 
normal fed rats. On the other hand, glucose uptake was not changed by insulin's action in the 
diabetic rats. This is probably explained by the measurement of a decrease in cerebral InR 
density in the diabetic animals by us. Since this decrease was accompanied with a decrease 
in CB1R density, it is possible that InR and CB1R bearing synapses require insulin as a 
trophic factor (Al-Mubarak et al., 2009) and, in their absence, synaptic dysfunction may take 
place leading to loss of cerebral insulin and cannabinoid sensitivity. 
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Finally, the deletion of the CB1R resulted in similar phenotype as the acute action of 
insulin and the lack of CB1Rs occluded the action of insulin. These findings point out that 
insulin requires the presence of functional CB1Rs to act upon synaptic transmission and 
glucose uptake. It is somewhat surprising that the CB1R KO exhibits an impaired instead of 
facilitated glucose uptake phenotype, because our research group has recently found that 
CB1Rs situated in neuronal and glial mitochondria actually negatively affect glucose 
metabolism, without impinging on the bioavailability of several other high-energy nutrients 
such as lactate. These differences may be explained with putative developmental alterations 
associated with CB1R deletion. 
 
 
3.4. Both InR and CB1R are localized in the postsynaptic active zone of mice and 
human cortices. 
 
Since there is evidence of the effect of insulin on synaptic transmission and glucose 
uptake to be dependent on the CB1R signalling in cortical and hippocampal slices and that 
this mostly postsynaptic effect, preliminary experiments of Western blot analysis were 
performed as previously validated (Rebola et al., 2005), with the aim of studying the 
localization of both InR and CB1R in the pre and postsynaptic active zones, in tissue 
preparations, as previously done (Köfalvi et al., 2005). 
Before assessing the localization of InR and CB1R in C57BL/6j mice cortex, the purity 
of subsynaptic fractions was validated by Western blot, with antibodies that label the 
presynaptic active zone (anti-SNAP-25), the postsynaptic zone (anti-PSD-95) and the 
extrasynaptic regions (anti-synaptophysin) (Figure 3.11 A). As expected, an enrichment of 
subsynaptic proteins was observed in the corresponding subsynaptic fractions. In detail: 
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SNAP-25 is the synaptosomal-associated protein 25 (with 25 kDa) and is located in the 
presynaptic fraction, PSD-95 is the post-synaptic density 95 (95 kDa) so it has a higher 
density in the postsynaptic fraction and synaptophysin is a synaptic vesicle marker (with 
38 kDa) which is therefore enriched in the extrasynaptic fraction. Total means the total 
initial crude from the synaptosomal preparation which was further processed in subsynaptic 
fractionation as explained in the chapter of Materials and Methods as well as in Köfalvi et al. 
(2005) (Figure 3.11 A). 
Afterwards, Western blot analysis carried out in these total synaptosomes and 
sub-synaptosomal fractions of mice cortices served evidence that the CB1R (with apparent 
molecular mass of 55 kDa) was specially enriched in the postsynaptic fraction, but it was 
also present in lower density at the presynaptic density fraction and in the other cell 
compartments fraction (extra) (Figure 3.11 B). InR (91 kDa) was also present in presynaptic 
and postsynaptic fractions, but it was enriched in the extrasynaptic fraction. Hence, CB1R 
and InR seem to be localized both pre and especially postsynaptically in the mouse cortex, 
but it is important to increase the number of experiments to draw definite conclusions about 
this (Figure 3.11 B). 
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Figure 3.11. CB1R and InR are localized both pre and postsynaptically in mice cortex. (A) 
Validation of the subsynaptic fractions by analysis of the enrichment of subsynaptic proteins in the 
corresponding subsynaptic fractions: SNAP-25 had a higher expression in the presynaptic fraction, 
PSD-95 was only present in the postsynaptic fraction and synaptophysin was enriched in the 
extrasynaptic fraction of mice cortices. (B) Western blot analysis of the localization of CB1R and InR 
in synaptosomal pre, post and extrasynaptic fractions of mice cortices revealed that the CB1R is 
mainly localized in the postsynaptic fraction and the InR is present both pre and postsynaptically but 
it is enriched in the extrasynaptic fraction. Total corresponds to the total synaptosomes which was 
further subsynaptically fractionated and, thus, it comprehends all fractions working as an internal 
positive control. 
 
Western blotting of human cortex samples showed that InR and CB1R are both present 
in the postsynaptic fraction and InRs are also present in the presynaptic active zone fraction 
(Figure 3.12). SNAP-25, PSD-95 and synaptophysin were used again to validate the purity 
of subsynaptic fractions and total synaptosomes were used as an internal positive control of 
the experiment. Thus, CB1R as well as InR seem to be localized in the presynaptic active 
zone of the human cortex (Figure 3.12). 
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Figure 3.12. Both CB1R and InR are postsynaptically localized in the human cortex. (A) 
Representative western blot of the localization of CB1R and InR in subsynaptic fractions of the 
human cortex, showing that both CB1R and InR are mainly localized in the synaptosomal 
postsynaptic fraction and the InR is also present in the presynaptic fraction. The validation of the 
purity of subsynaptic fractions was made with SNAP-25, PSD-95 and synaptophysin. The total 
synaptosomes were used as an internal positive control of the experiment. (B) Graphic of the 
percentage of immunoreactivity for InR and CB1R bands, which was calculated considering the sum 
of the pre, extra and postsynaptic fractions value as 100%. Data are mean ± SEM of n = 2 
independent experiments. 
 
In spite of the presynaptic CB1Rs in various brain regions being better established 
(Freund et al., 2003), CB1Rs were already detected postsynaptically in rat neocortical 
GABAergic and pyramidal cells, where their activation promotes slow-self inhibition 
(Marinelli et al., 2008). Postsynaptic CB1Rs were also found in rodent striatum (Köfalvi et 
al., 2005), in rat spinal cord (Salio et al., 2002) and in other brain areas (Freund et al., 2003). 
Thus, it is possible that both CB1R and InR are located at the postsynaptic active zone. 
Both CB1R activation (Kim et al., 2011) and inhibition (Bouaboula et al., 1997) have 
already been reported to inhibit insulin signalling in different conditions, but it is still 
unknown if the CB1R and the InR interact through a heteromeric manner or through 
intracellular messengers in the brain. Recently, the modulation of insulin secretion by eCBs 
was proposed in pancreatic cells, which may be dependent on local metabolism and cellular 
conditions (Anderson et al., 2013). Besides, it was recently shown that CB1Rs form 
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heteromeric complexes with RTKs, including the InR (Dalton and Howlett, 2012 and Kim et 
al., 2012). Therefore, after studying that the insulin action in rodent hippocampus synaptic 
transmission and in hippocampus and cortex glucose uptake are CB1R dependent and after 
predicting they are both located postsynaptically, it is possible to hypothesize that probably 
the interaction between the CB1R and the InR can be though a heteromeric manner or, most 
probably, through some secondary messenger molecules. Alternatively, as the recent study 
of Labouèbe and colleagues (2013) has demonstrated, the activation of InR may promote 
eCB release which, in turn, would act on CB1Rs to exert diverse functions. At the present 
stage we can not speculate with certainty whether the interaction between the two receptors 
is direct or indirect. 
 
  
 
 
 
 
 
4. CONCLUSIONS 
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The present study demonstrates that insulin effect under both synaptic transmission 
and glucose uptake in hippocampal and, for glucose uptake, cortical slices of Wistar rats is 
disturbed by alterations in the CB1R activity. Significant alterations were also observed in 
synaptic transmission of hippocampal slices of fasted and two weeks STZ rats. Furthermore, 
insulin regulation of glucose uptake on cortical and hippocampal slices of wild-type mice 
seems to be similar to the pre-existing alterations in the CB1R KO mice. The CB1R deletion 
in mice has also shown to be insulin insensitive. Finally, preliminary studies of IR and CB1R 
localization in the subsynaptic fractions of mice and human cortices showed that they are 
both present in the postsynaptic active zone. 
Therefore, this work shows that insulin signalling depends on the eCB system in the 
brain and provides evidence for a possible functional interaction between an insulin-sensitive 
receptor (likely the IR) and the CB1R in cortex and hippocampus (both brain areas related to 
learning and memory). Both IR and CB1R signalling pathways have metabolites in common, 
although it seems to be a direct or a protein mediated physical interaction between the two 
receptors. 
Further molecular studies are necessary to explore if this functional interaction 
happens between the CB1R and the IR (rather than the IFG-1R) and if it involves the 
formation of heterodimmers, which could be verified with a co-immunoprecipitation assay. 
Then, if the two receptors do not form heterodimmers, it probably means that they interact 
through another pathway, shorter than through their common metabolites. Hence, 
co-localization of both receptors could be studied using confocal microscopy, for instance. 
However, if they interact directly, this reveals a new target of study for neurodegenerative 
(like AD) and psychiatric disorders. Besides, the methods used in this work could be 
repeated in human subjects using MRI and PET imaging techniques. 
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